QQ客服 官方微博 反馈留言

	Class I HDAC Inhibitors Display Different Antitumor Mechanism in Leukemia and Prostatic Cancer Cells Depending on Their p53 Status
	Li, Xiaoyang; Peterson, Yuri K.; Inks, Elizabeth S.; Himes, Richard A.; Li, Jiaying; Zhang, Yingjie; Kong, Xiujie; Chou, C. James
刊名	JOURNAL OF MEDICINAL CHEMISTRY
	2018
卷号	61期号:6页码:2589-2603
DOI	10.1021/acs.jmedchem.8b00136
URL标识	查看原文
公开日期	[db:dc_date_available]
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/4567162
专题	山东大学
作者单位	Med Univ South Carolina, South Carolina Coll Pharm, Dept Drug Disco
推荐引用方式 GB/T 7714	Li, Xiaoyang,Peterson, Yuri K.,Inks, Elizabeth S.,et al. Class I HDAC Inhibitors Display Different Antitumor Mechanism in Leukemia and Prostatic Cancer Cells Depending on Their p53 Status[J]. JOURNAL OF MEDICINAL CHEMISTRY,2018,61(6):2589-2603.
APA	Li, Xiaoyang.,Peterson, Yuri K..,Inks, Elizabeth S..,Himes, Richard A..,Li, Jiaying.,...&Chou, C. James.(2018).Class I HDAC Inhibitors Display Different Antitumor Mechanism in Leukemia and Prostatic Cancer Cells Depending on Their p53 Status.JOURNAL OF MEDICINAL CHEMISTRY,61(6),2589-2603.
MLA	Li, Xiaoyang,et al."Class I HDAC Inhibitors Display Different Antitumor Mechanism in Leukemia and Prostatic Cancer Cells Depending on Their p53 Status".JOURNAL OF MEDICINAL CHEMISTRY 61.6(2018):2589-2603.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。